BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xue J, Suarez JS, Minaai M, Li S, Gaudino G, Pass HI, Carbone M, Yang H. HMGB1 as a therapeutic target in disease. J Cell Physiol 2021;236:3406-19. [PMID: 33107103 DOI: 10.1002/jcp.30125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Mohammad G, Kowluru RA. Involvement of High Mobility Group Box 1 Protein in Optic Nerve Damage in Diabetes. EB 2022;Volume 14:59-69. [DOI: 10.2147/eb.s352730] [Reference Citation Analysis]
2 Chernyak BV, Lyamzaev KG, Mulkidjanian AY. Innate Immunity as an Executor of the Programmed Death of Individual Organisms for the Benefit of the Entire Population. Int J Mol Sci 2021;22:13480. [PMID: 34948277 DOI: 10.3390/ijms222413480] [Reference Citation Analysis]
3 Burgoyne RA, Fisher AJ, Borthwick LA. The Role of Epithelial Damage in the Pulmonary Immune Response. Cells 2021;10:2763. [PMID: 34685744 DOI: 10.3390/cells10102763] [Reference Citation Analysis]
4 Farhana A, Koh AE, Tong JB, Alsrhani A, Kumar Subbiah S, Mok PL. Nanoparticle-Encapsulated Camptothecin: Epigenetic Modulation in DNA Repair Mechanisms in Colon Cancer Cells. Molecules 2021;26:5414. [PMID: 34500845 DOI: 10.3390/molecules26175414] [Reference Citation Analysis]
5 Totoki T, Ito T, Yamada S, Honda G, Hattori T, Maruyama I. Specific detection of high mobility group box 1 degradation product with a novel ELISA. Mol Med 2021;27:59. [PMID: 34107884 DOI: 10.1186/s10020-021-00323-1] [Reference Citation Analysis]
6 Salo H, Qu H, Mitsiou D, Aucott H, Han J, Zhang XM, Aulin C, Erlandsson Harris H. Disulfide and Fully Reduced HMGB1 Induce Different Macrophage Polarization and Migration Patterns. Biomolecules 2021;11:800. [PMID: 34071440 DOI: 10.3390/biom11060800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kabe Y, Koike I, Yamamoto T, Hirai M, Kanai A, Furuhata R, Tsugawa H, Harada E, Sugase K, Hanadate K, Yoshikawa N, Hayashi H, Noda M, Uchiyama S, Yamazaki H, Tanaka H, Kobayashi T, Handa H, Suematsu M. Glycyrrhizin Derivatives Suppress Cancer Chemoresistance by Inhibiting Progesterone Receptor Membrane Component 1. Cancers (Basel) 2021;13:3265. [PMID: 34209885 DOI: 10.3390/cancers13133265] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Liu L, Li L, Li M, Luo Z. Autophagy-Dependent Ferroptosis as a Therapeutic Target in Cancer. ChemMedChem 2021. [PMID: 34110079 DOI: 10.1002/cmdc.202100334] [Reference Citation Analysis]
9 Otazu GK, Dayyani M, Badie B. Role of RAGE and Its Ligands on Inflammatory Responses to Brain Tumors. Front Cell Neurosci 2021;15:770472. [PMID: 34975408 DOI: 10.3389/fncel.2021.770472] [Reference Citation Analysis]
10 Zhang Z, Zhou J, Verma V, Liu X, Wu M, Yu J, Chen D. Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury. Front Immunol 2021;12:774807. [PMID: 34925345 DOI: 10.3389/fimmu.2021.774807] [Reference Citation Analysis]
11 Wang J, Wu C, Wang Y, Chen C, Cheng J, Rao X, Sun H. The Role of HMGB1 in Invasive Candida albicans Infection. Mycopathologia 2021;186:789-805. [PMID: 34608551 DOI: 10.1007/s11046-021-00595-5] [Reference Citation Analysis]
12 Xiong Y, Yang J, Tong H, Zhu C, Pang Y. HMGB1 augments cognitive impairment in sepsis-associated encephalopathy by binding to MD-2 and promoting NLRP3-induced neuroinflammation. Psychogeriatrics 2021. [PMID: 34931753 DOI: 10.1111/psyg.12794] [Reference Citation Analysis]
13 Štros M, Polanská EV, Hlaváčová T, Skládal P. Progress in Assays of HMGB1 Levels in Human Plasma—The Potential Prognostic Value in COVID-19. Biomolecules 2022;12:544. [DOI: 10.3390/biom12040544] [Reference Citation Analysis]
14 Torrecillas-Baena B, Gálvez-Moreno MÁ, Quesada-Gómez JM, Dorado G, Casado-Díaz A. Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review. Stem Cell Rev Rep 2021. [PMID: 34677817 DOI: 10.1007/s12015-021-10285-w] [Reference Citation Analysis]
15 Song B, Bie Y, Feng H, Xie B, Liu M, Zhao F. Inflammatory factors driving atherosclerotic plaque progression new insights. Journal of Translational Internal Medicine 2022;10:36-47. [DOI: 10.2478/jtim-2022-0012] [Reference Citation Analysis]
16 Li L, Liu H, Tao W, Wen S, Fu X, Yu S. Pharmacological Inhibition of HMGB1 Prevents Muscle Wasting. Front Pharmacol 2021;12:731386. [PMID: 34867338 DOI: 10.3389/fphar.2021.731386] [Reference Citation Analysis]
17 Zhu D, Zou H, Liu J, Wang J, Ma C, Yin J, Peng X, Li D, Yang Y, Ren Y, Zhang Z, Zhou P, Wang X, Cao Y, Xu X. Inhibition of HMGB1 Ameliorates the Maternal-Fetal Interface Destruction in Unexplained Recurrent Spontaneous Abortion by Suppressing Pyroptosis Activation. Front Immunol 2021;12:782792. [PMID: 35003098 DOI: 10.3389/fimmu.2021.782792] [Reference Citation Analysis]
18 Frisardi V, Matrone C, Street ME. Metabolic Syndrome and Autophagy: Focus on HMGB1 Protein. Front Cell Dev Biol 2021;9:654913. [PMID: 33912566 DOI: 10.3389/fcell.2021.654913] [Reference Citation Analysis]
19 Bailly C. Acankoreagenin and acankoreosides, a family of lupane triterpenoids with anti-inflammatory properties: an overview. Ann N Y Acad Sci 2021;1502:14-27. [PMID: 34145915 DOI: 10.1111/nyas.14623] [Reference Citation Analysis]
20 Fei L, Zhang N, Zhang J. Mechanism of miR-126 in hypoxia-reoxygenation-induced cardiomyocyte pyroptosis by regulating HMGB1 and NLRP3 inflammasome. Immunopharmacol Immunotoxicol 2022;:1-24. [PMID: 35297734 DOI: 10.1080/08923973.2022.2054819] [Reference Citation Analysis]
21 Huang P, Zhu S, Liang X, Zhang Q, Liu C, Song L. Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs. Technol Cancer Res Treat 2021;20:15330338211038488. [PMID: 34431723 DOI: 10.1177/15330338211038488] [Reference Citation Analysis]
22 Chen Y, Zhang W, Bao H, He W, Chen L. High Mobility Group Box 1 Contributes to the Acute Rejection of Liver Allografts by Activating Dendritic Cells. Front Immunol 2021;12:679398. [PMID: 34177922 DOI: 10.3389/fimmu.2021.679398] [Reference Citation Analysis]
23 Ge Y, Huang M, Yao YM. The Effect and Regulatory Mechanism of High Mobility Group Box-1 Protein on Immune Cells in Inflammatory Diseases. Cells 2021;10:1044. [PMID: 33925132 DOI: 10.3390/cells10051044] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 Zhu L, Ren S, Daniels MJ, Qiu W, Song L, You T, Wang D, Wang Z. Exogenous HMGB1 Promotes the Proliferation and Metastasis of Pancreatic Cancer Cells. Front Med (Lausanne) 2021;8:756988. [PMID: 34805222 DOI: 10.3389/fmed.2021.756988] [Reference Citation Analysis]
25 Makris G, Chouliaras G, Apostolakou F, Papageorgiou C, Chrousos GP, Papassotiriou I, Pervanidou P. Increased Serum Concentrations of High Mobility Group Box 1 (HMGB1) Protein in Children with Autism Spectrum Disorder. Children (Basel) 2021;8:478. [PMID: 34198762 DOI: 10.3390/children8060478] [Reference Citation Analysis]
26 Voong CK, Goodrich JA, Kugel JF. Interactions of HMGB Proteins with the Genome and the Impact on Disease. Biomolecules 2021;11:1451. [PMID: 34680084 DOI: 10.3390/biom11101451] [Reference Citation Analysis]
27 Michetti F, Di Sante G, Clementi ME, Sampaolese B, Casalbore P, Volonté C, Romano Spica V, Parnigotto PP, Di Liddo R, Amadio S, Ria F. Growing role of S100B protein as a putative therapeutic target for neurological- and nonneurological-disorders. Neurosci Biobehav Rev 2021;127:446-58. [PMID: 33971224 DOI: 10.1016/j.neubiorev.2021.04.035] [Reference Citation Analysis]